Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
Attempts to produce a vaccine to human cytomegalovirus (HCMV) have failed. The principal target of the humoral immune response to HCMV is the viral envelope glycoprotein gB, which contains several immunodominant epitopes. Here we discuss human antibodies reacting with gB and offer an explanation as to why most humans make antibodies to an epitope that does not always elicit neutralizing antibodies. We suggest modifications to gB for an improved HCMV vaccine design.
Schrader
John W
JW
McLean
Gary R
GR
D000914:Antibodies, Viral; D000917:Antibody Formation; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control*; D022482:Cytomegalovirus Vaccines; D018604:Epitope Mapping; D006801:Humans; D016056:Immunodominant Epitopes; D009500:Neutralization Tests; D011487:Protein Conformation; D013997:Time Factors; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000276:immunology*
D000914:Antibodies, Viral; D022482:Cytomegalovirus Vaccines; D016056:Immunodominant Epitopes; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus